Who's left? Symptoms of schizophrenia that predict clinical trial dropout

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 609-613

  Thompson, Jason ^a   Berk, Michael ^a   Dean, Olivia ^b   Kohlmann, Kristy ^b   Jeavons, Sue ^b   Bush, Ashley ^b   Copolov, David ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

adherence; completion; dropout; Lindenmayer; negative symptoms; schizophrenia

Indexed keywords

ACETYLCYSTEINE;

ADULT; AGED; ANXIETY; ARTICLE; DEPRESSION; EXCITEMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PATIENT DROPOUTS; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 83855165077     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1253     Document Type: Article

References (16)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th revised edn. APA: Washington, USA.
2. Andreasen NC,. 1989. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 155: 49-52.
3. Axelrod BN, Goldman RS, Woodard JL, Alphs LD,. 1994. Factor structure of the negative syndrome assessment. Psychiatry Res 52: 173-179.
4. Berk M, Copolov D, Dean O, et al,. 2008. N-Acetyl cysteine as a glutathione precursor for schizophrenia-a double blind, randomised placebo-controlled trial. Biol Psychiatry 64: 361-368.
5. Cramer JA, Rosenheck R,. 1998. Compliance with medication regimens for medical and physical disorders. Psychiatr Serv 49: 196-201.
6. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJH, Rabinowitz J,. 2008. Long-acting injectable rispiridone in the treatment of subjects with recent onset psychosis. J Clin Psychopharmacol 28: 210-213.
7. Fenton WS, Blyer CR, Heinssen RK,. 1997. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23: 637-651.
8. Kane J, Canas F, Kramer M, et al,. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90: 147-161.
9. Lindenmayer JP, Bernstein-Hyman R, Grochowski S,. 1994. Five factor model of schizophrenia: initial validation. J Nerv Ment Dis 182: 631-638.
10. Lindenmayer JP, Bernstein-Hyman R, Grochowski S,. 1995. Five factor model of schizophrenia: replication across samples. Schizophr Res 14: 229-234.
11. Lindenmayer JP, Brown E, Baker RW, et al,., 2004. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Research 68: 331-337.
12. Lindenmayer JP, Harvey PD, Khan A, Kirkpatrick B,. 2007. Schizophrenia: Measurements of psychopathology. Psychiatric Clinics of North America 30: 339-363.
13. Mocks J, Kohler W, Scott M, Maurer J, Budde M, Givens S,. 2002. Dealing with selective dropout in clinical trials. Pharm Stat 1: 119-130.
14. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L,. 2009. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 110: 80-89.
15. Trueur T, Anders M, Bitter I, et al,. 2006. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe; results after 1 year from a prospective, observational study (IC-SOHO). Int J Psychiatry Clin Pract 10: 78-90.
16. Wahlbeck K, Tuunainan A, Ahokas A, Leucht S,. 2001. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155: 230-233.